Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cataldo Patruno

Showing results (1-10 of 298) with videos related to

Pageof 30
Sort By:
Medical Hypotheses|June 3, 2018
Aryl hydrocarbon receptor (AhR) a possible target for the treatment of skin diseaseMaddalena Napolitano, Cataldo Patruno
Med (New York, N.Y.)|November 9, 2024
ARCADIA trials: Can nemolizumab be a valid alternative to the therapies currently available?Maddalena Napolitano, Cataldo Patruno
Journal of the American Academy of Dermatology|April 28, 2020
Reply: Potential role of Janus kinase inhibitors in COVID-19Maddalena Napolitano, Gabriella Fabbrocini, Cataldo Patruno
The Journal of Dermatology|March 14, 2023
Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective studyMaddalena Napolitano, Gabriella Fabbrocini, Cataldo Patruno
Italian Journal of Dermatology and Venereology|March 27, 2026
West Nile virus: a diagnostic challenge for dermatologistsClaudio Brescia, Maddalena Napolitano, Cataldo Patruno
The Australasian Journal of Dermatology|July 15, 2024
Comment on 'Dupilumab for atopic dermatitis in metastatic cancer'Luca Potestio, Cataldo Patruno, Maddalena Napolitano
Journal of the European Academy of Dermatology and Venereology : JEADV|June 21, 2025
Reply to 'Real-world experience of switching from tralokinumab to lebrikizumab in atopic dermatitis'Fabrizio Martora, Cataldo Patruno, Maddalena Napolitano
Clinical and Experimental Dermatology|May 13, 2025
Comment on 'Potential Role of Leptin in JAK2 Inhibitor-Associated Weight Gain: A Monocentric Retrospective Study'Luca Potestio, Cataldo Patruno, Maddalena Napolitano
Dermatitis : Contact, Atopic, Occupational, Drug|November 14, 2023
Efficacy and Safety of Tralokinumab in Real Life: Possible Predictive Rapid Response FactorsLuca Potestio, Cataldo Patruno, Maddalena Napolitano
Italian Journal of Dermatology and Venereology|January 23, 2024
Severe symptomatic late onset dermographism after mRNA COVID-19 vaccineCataldo Patruno, Gabriella Fabbrocini, Maddalena Napolitano
Pageof 30

Showing results (1-10 of 298) with videos related to

Sort By:
Pageof 30
Medical Hypotheses|June 3, 2018
Aryl hydrocarbon receptor (AhR) a possible target for the treatment of skin diseaseMaddalena Napolitano, Cataldo Patruno
Med (New York, N.Y.)|November 9, 2024
ARCADIA trials: Can nemolizumab be a valid alternative to the therapies currently available?Maddalena Napolitano, Cataldo Patruno
Journal of the American Academy of Dermatology|April 28, 2020
Reply: Potential role of Janus kinase inhibitors in COVID-19Maddalena Napolitano, Gabriella Fabbrocini, Cataldo Patruno
The Journal of Dermatology|March 14, 2023
Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective studyMaddalena Napolitano, Gabriella Fabbrocini, Cataldo Patruno
Italian Journal of Dermatology and Venereology|March 27, 2026
West Nile virus: a diagnostic challenge for dermatologistsClaudio Brescia, Maddalena Napolitano, Cataldo Patruno
The Australasian Journal of Dermatology|July 15, 2024
Comment on 'Dupilumab for atopic dermatitis in metastatic cancer'Luca Potestio, Cataldo Patruno, Maddalena Napolitano
Journal of the European Academy of Dermatology and Venereology : JEADV|June 21, 2025
Reply to 'Real-world experience of switching from tralokinumab to lebrikizumab in atopic dermatitis'Fabrizio Martora, Cataldo Patruno, Maddalena Napolitano
Clinical and Experimental Dermatology|May 13, 2025
Comment on 'Potential Role of Leptin in JAK2 Inhibitor-Associated Weight Gain: A Monocentric Retrospective Study'Luca Potestio, Cataldo Patruno, Maddalena Napolitano
Dermatitis : Contact, Atopic, Occupational, Drug|November 14, 2023
Efficacy and Safety of Tralokinumab in Real Life: Possible Predictive Rapid Response FactorsLuca Potestio, Cataldo Patruno, Maddalena Napolitano
Italian Journal of Dermatology and Venereology|January 23, 2024
Severe symptomatic late onset dermographism after mRNA COVID-19 vaccineCataldo Patruno, Gabriella Fabbrocini, Maddalena Napolitano
Pageof 30